NCT01143467

Brief Summary

Background: \- Fatigue is a very common early and late side effect of cancer treatment, including radiation therapy. The cause of fatigue is poorly understood, making it hard to diagnose and treat. More research is necessary to understand why patients receiving cancer treatment experience fatigue. Changes in mitochondria, parts of body cells that help provide energy to the cell, may contribute to fatigue. Researchers are interested in looking at blood chemicals and mitochondrial genes of cancer patients to study those associated with fatigue. Objectives: \- To study the relationship between fatigue and the effects of cancer treatment. Eligibility:

  • Men at least 18 years of age who have been diagnosed with localized prostate cancer and are scheduled to receive external beam radiation therapy.
  • Participants on study 09-NR-0088, Molecular-Genetic Correlates of Fatigue in Cancer Patients Receiving External Beam Radiation Therapy, are also eligible. Design:
  • This study requires three outpatient visits to the NIH Clinical Center.
  • Participants will be seen before they start radiation treatment, at the middle of treatment, and at the end of treatment. Each visit will take less than 30 minutes to complete.
  • Participants will complete questionnaires that ask about fatigue and depression.
  • Participants will provide blood samples for research testing and potential HIV testing.
  • No treatment will be provided as part of this protocol.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2010

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 24, 2010

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

June 11, 2010

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 14, 2010

Completed
5.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 6, 2015

Completed
Last Updated

October 6, 2017

Status Verified

November 6, 2015

First QC Date

June 11, 2010

Last Update Submit

October 5, 2017

Conditions

Keywords

FatigueMitochondriaMitochondrial AbnormalityOxidative StressGene ExpressionProstate Cancer

Eligibility Criteria

Age18 Years - 100 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinically localized prostate cancer;
  • Scheduled to receive EBRT either by 3D conformal or IMRT techniques that is not anticipated to change during the course of the study, with or without Androgen Deprivation Therapy (ADT);
  • Able to provide written informed consent;
  • Men greater than or equal to 18 years of age;
  • Have enrolled in the study of molecular-genetic correlates of fatigue in cancer patients receiving localized radiation therapy (09-NR-0088).

You may not qualify if:

  • A. Any condition other than prostate cancer able to cause clinically significant fatigue including cardiovascular, pulmonary, gastrointestinal, central nervous system, psychiatric, endocrine, hematologic, renal, or immunologic disorders, and including patients with any of the following broad disease categories:
  • Systemic infections (e.g., human immunodeficiency virus \[HIV\], active hepatitis);
  • Documented history of major depression, bipolar disease, psychosis, or alcohol dependence/abuse within the past 5 years;
  • Uncorrected hypothyroidism and anemia;
  • Chronic inflammatory disease that may be anticipated to alter the proinflammatory cytokine profile (i.e. rheumatoid arthritis, systemic lupus erythematosus, cirrhosis).
  • B. Patients taking tranquilizers, steroids, and nonsteroidal anti-inflammatory agents because these medications are known to affect cytokine production;
  • C. Patients who have second malignancies or those receiving chemotherapy with their EBRT.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

  • Lemle MD. Hypothesis: chronic fatigue syndrome is caused by dysregulation of hydrogen sulfide metabolism. Med Hypotheses. 2009 Jan;72(1):108-9. doi: 10.1016/j.mehy.2008.08.003. Epub 2008 Sep 16. No abstract available.

    PMID: 18799269BACKGROUND
  • Greenberger JS. Radioprotection. In Vivo. 2009 Mar-Apr;23(2):323-36.

    PMID: 19414422BACKGROUND
  • Cheville AL. Cancer-related fatigue. Phys Med Rehabil Clin N Am. 2009 May;20(2):405-16. doi: 10.1016/j.pmr.2008.12.005.

    PMID: 19389620BACKGROUND

MeSH Terms

Conditions

NeoplasmsFatigueProstatic Neoplasms

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and SymptomsGenital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Officials

  • Leorey N Saligan, C.R.N.P.

    National Institute of Nursing Research (NINR)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 11, 2010

First Posted

June 14, 2010

Study Start

May 24, 2010

Study Completion

November 6, 2015

Last Updated

October 6, 2017

Record last verified: 2015-11-06

Locations